All News

"These tests, germline and tumor somatic testing, are extremely important and can no longer be ignored in the clinic when we see these patients," says Neeraj Agarwal, MD.

“The ClarityDX Prostate test will reduce the number of unnecessary prostate biopsies, which are invasive, uncomfortable, and carry some risk,” says John D. Lewis, PhD.

Artificial intelligence can help curate, decipher, and contextualize the enormous and growing amount of digital data that now comprises a patient’s electronic health record, writes Nele Jessel, MD.

Cleveland Clinic is the first to investigate photonic nanoparticles as a potential kidney stone treatment.

Preliminary findings from the study showed a decrease in PSA levels across all doses of PDS0301 assessed.

In this installment, Christopher E. Ramsey, MD, FACS, and Rachel Vann, MSN, RN, NP-C, highlight Tennessee Urology, an affiliate of United Urology Group.

These findings may help guide decision-making in the initial testing phase of the [sacral neuromodulation] device prior to permanent implant or explant, according to Bradley Gill, MD, of the Cleveland Clinic.

“These findings demonstrate that electrofulguration provides a durable clinical cure that enables many postmenopausal women to remain UTI-free with minimal to no continued need for antibiotic therapy," says Philippe E. Zimmern, MD.

The Invitae Common Hereditary Cancers Panel utilizes DNA taken from a blood sample to identify the presence of variants in 47 genes linked to an increased risk of developing certain cancers.

At 3 months following treatment, 50% of men who received CCH injections reported being “very satisfied” overall, compared with 21% of patients in the surgery group.

In patients with microhematuria, a positive result on the test was associated with a 5-fold increase in the risk of patients harboring bladder cancer compared with current metrics alone.

Increased retrovesicourethral angle, decreased functional urethral length, and the presence of bladder funnel were pelvic floor parameters identified as potential predictors of stress urinary incontinence in the early postpartum period.

An approach combining chemotherapy and immunotherapy could help preserve quality of life.

When compared with standard risk factors, only Decipher Prostate Genomic Classifier scores were independently associated with metastasis-free survival and distant metastasis.

"A lot of patients with prostate cancer are going to receive one of these agents," says Tanya B. Dorff, MD.

"Make the proper beneficiary designation adjustments when warranted and review these annually with your adviser to ensure they remain up-to-date and make financial sense given your current situation," writes Jeff Witz, CFP.

“Patients who are candidates for bariatric surgery should be advised that improvement in urinary incontinence may also be a significant benefit of their intervention,” the authors wrote.

"If additional research confirms our findings, this may lead to a new paradigm in the treatment of muscle-invasive bladder cancer," says Matthew Galsky, MD.

"The question of when a surgeon should retire has been the subject of debate for decades," writes Raj S. Pruthi, MD.

"I treat all aspects of male and female incontinence, whether this be artificial urinary sphincter, the male sling, female sling, bladder Botox, or sacral neuromodulation," said Jas Singh, MD, FRCS.

Treatment with adjuvant pembrolizumab reduced the risk of disease recurrence or death versus observation in patients with localized muscle-invasive urothelial carcinoma and locally advanced urothelial carcinoma.

"ICD-10-CM coding denials have been increasing across the country as payers continue to refine edits," write Jonathan Rubenstein, MD, and Mark Painter.

The study achieved 100% local control and cancer-specific mortality rates with stereotactic ablative body radiotherapy.

"Psychological factors often have an important role [in erectile dysfunction], and psychological treatment options are available that have been found to improve outcomes," said Mark S. Allen, PhD.

This is the largest prostate cancer study that examined the exome, according to the researchers, who believe their findings can potentially inform the makeup of panels used for genetic testing in prostate cancer.

"Results showed that more than two-thirds of these men were found to have positive Posluma scans, with a quarter of them having extrapelvic lesions," says Ashesh B. Jani, MD, MSEE, FASTRO.

Data showed that the proportion of Black patients referred for genomic testing increased from 19% to 58% after the implementation of the precision medicine navigator.

The phase 1/2 COMBAT study examining the novel theranostic 64Cu/67Cu-SAR-Bombesin.